A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists
Year: 2004
Type: article
Source: Journal of Medicinal Chemistry
DOI: 10.1021/jm0492507
Authors: Jeffrey J. Hale, Christopher L. Lynch, William Neway, Sander G. Mills, Richard Hajdu, Carol Ann Keohane, Mark J. Rosenbach, James A. Milligan, Gan-Ju Shei, Stephen A. Parent, Gary Chrebet, James Bergstrom, Deborah Card, Marc Ferrer, Peter Hodder, Berta Strulovici, Hugh Rosen, Suzanne Mandala
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1969141508